Helliwell Philip S, Gladman Dafna D, Gottlieb Alice B
From GRAPPA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; New York Medical College, Valhalla, New York, USA.
P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust, and President, GRAPPA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, Toronto Western Hospital, and Co-Chair, GRAPPA Publication Committee; A.B. Gottlieb, MD, PhD, Professor of Dermatology, New York Medical College, and Co-Chair, GRAPPA Publication Committee.
J Rheumatol. 2017 May;44(5):658-660. doi: 10.3899/jrheum.170139.
The 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Miami, Florida, USA, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. As in previous years, GRAPPA members held a symposium for trainees to discuss their research in psoriatic disease with experts in the field. A strategic planning session was convened by the Steering Committee this year to review the work of GRAPPA since its inception in 2003. Other subjects featured during the annual meeting included a partnership with KPMG LLP (UK) to conduct interviews at research centers worldwide to analyze the process of care in psoriasis and psoriatic arthritis (PsA); a discussion of the effects of interleukin 17-related pathways on the skin and joints in psoriasis and PsA; summaries of recently published treatment recommendations and related guides; 4 separate discussions of psoriasis patient examinations; updates from working groups in the Outcome Measures in Rheumatology and the International Dermatology Outcome Measures; a discussion of patient centricity from GRAPPA's patient research partners; and an update of research and educational projects from GRAPPA. In this prologue, we introduce the papers that summarize that meeting.
银屑病和银屑病关节炎研究与评估小组（GRAPPA）2016年年会在美国佛罗里达州迈阿密举行，参会人员包括风湿病学家、皮肤科医生、生物制药公司代表和患者团体代表。与往年一样，GRAPPA成员为实习生举办了一场研讨会，以便他们与该领域的专家讨论自己在银屑病疾病方面的研究。今年，指导委员会召开了一次战略规划会议，以回顾GRAPPA自2003年成立以来的工作。年会期间的其他主题包括与毕马威会计师事务所（英国）合作，在全球研究中心进行访谈，以分析银屑病和银屑病关节炎（PsA）的护理过程；讨论白细胞介素17相关通路对银屑病和PsA皮肤及关节的影响；总结近期发布的治疗建议和相关指南；4场关于银屑病患者检查的单独讨论；风湿病学疗效指标工作组和国际皮肤病学疗效指标工作组的工作进展；GRAPPA患者研究合作伙伴关于以患者为中心的讨论；以及GRAPPA研究和教育项目的进展情况。在这篇前言中，我们介绍了总结那次会议的论文。
